Pharmaceuticals

Rising Prevalence Of Chronic Kidney Disease (CKD) Driving The Market Growth Due To Increasing Risk Of Secondary Hyperparathyroidism Is Supporting Development Across The Parathyroid Disease Treatment Market

May 20, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Increase In Market Value Is Predicted For The Parathyroid Disease Treatment Market During The 2026–2030 Period?

The parathyroid disease treatment market has demonstrated significant expansion in recent years. It is anticipated to increase from $2.37 billion in 2025 to $2.54 billion in 2026, registering a compound annual growth rate (CAGR) of 7.2%. Historically, this market growth has been influenced by elements such as the growing occurrence of hyperparathyroidism, insufficient public knowledge about parathyroid ailments, a reliance on standard hormone replacement therapy, the scarcity of advanced surgical methods, and underdeveloped hospital pharmacy infrastructure.

The parathyroid disease treatment market size is projected for significant expansion over the next few years. It is anticipated to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. This growth during the forecast period can be attributed to the increasing demand for calcimimetics and bisphosphonates, advancements in parathyroid imaging and diagnostics, the rise of homecare and telemedicine solutions, regulatory support for precision medicine, and the expansion of specialty centers for endocrine disorders. Major trends in this period include the wider adoption of calcimimetics and bisphosphonates, a growing preference for parenteral over oral administration in severe cases, the enlargement of hospital and specialty care settings, an increased focus on personalized hormone replacement therapies, and the integration of lifestyle and nutritional interventions into treatment plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

Which Significant Factors Are Encouraging Growth In The Parathyroid Disease Treatment Market?

The increasing occurrence of chronic kidney disease (CKD) is anticipated to drive the expansion of the parathyroid disease treatment market in the future. CKD represents a persistent ailment characterized by a progressive decline in kidney function, resulting in mineral imbalances, particularly involving calcium and phosphorus. The growing incidence of chronic kidney disease (CKD) largely stems from the increasing cases of diabetes, given that sustained elevated blood sugar levels can progressively harm the kidney’s filtering structures, culminating in diabetic nephropathy. Addressing parathyroid disease is crucial for managing chronic kidney disease (CKD), as it focuses on secondary hyperparathyroidism, a common issue in advanced CKD that disturbs calcium and phosphorus equilibrium, fosters bone problems, and encourages the hardening of blood vessels. For example, data from May 2024, published by the US-based government public health agency, the Centers for Disease Control and Prevention (CDC), indicated that over one in seven adults in the US, totaling approximately 35.5 million people or about 14%, were projected to have chronic kidney disease in 2023, with nearly 90% of these individuals being unaware of their state. Consequently, the increasing occurrence of chronic kidney disease is propelling the expansion of the parathyroid disease treatment market.

How Are Different Segment Groups Identified Within The Parathyroid Disease Treatment Market?

The parathyroid disease treatment market covered in this report is segmented –

1) By Treatment: Calcimimetics, Bisphosphonates, Plicamycin, Hormone Replacement Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

4) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Calcimimetics: Cinacalcet, Etelcalcetide

2) By Bisphosphonates: Alendronate, Ibandronate, Risedronate, Zoledronic Acid

3) By Plicamycin: Mithramycin (Plicamycin) Monotherapy, Combination Therapies Involving Plicamycin

4) By Hormone Replacement Therapy: Estrogen Therapy, Progesterone Therapy, Combined Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs)

5) By Other Treatments: Parathyroid Hormone (PTH) Analogues, Surgery (Parathyroidectomy), Dietary Supplements, Lifestyle And Nutritional Interventions

Which Trends Are Affecting The Parathyroid Disease Treatment Market Framework?

Major companies operating in the parathyroid disease treatment market are focusing on the development of innovative products, such as parathyroid hormone prodrugs, to improve calcium regulation and reduce dosing frequency in patients with hypoparathyroidism. Parathyroid hormone (PTH) prodrugs are inactive compounds that convert into active PTH in the body to regulate calcium and phosphate balance. For instance, in August 2024, Ascendis Pharma A/S, a Denmark-based biopharmaceutical company, received US Food and Drug Administration (FDA) approval for YORVIPATH (palopegteriparatide), a prodrug of parathyroid hormone (PTH[1-34]), specifically for the treatment of chronic hypoparathyroidism in adults. This once-daily therapy provides continuous parathyroid hormone exposure over 24 hours, offering an alternative to conventional calcium and vitamin D supplementation by directly addressing the underlying hormone deficiency. The approval of YORVIPATH underscores the increasing emphasis on advanced hormone replacement therapies aimed at enhancing treatment adherence and delivering better clinical outcomes for patients with parathyroid disorders.

Who Are The Key Market Participants In The Parathyroid Disease Treatment Market?

Major companies operating in the parathyroid disease treatment market are AstraZeneca PLC, Amgen Inc., Kyowa Kirin Co. Ltd., OPKO Health Inc., Septerna Inc., Entera Bio Ltd., Visen Pharmaceuticals (Shanghai) Co. Ltd., Ascendis Pharma A/S, Aeterna Zentaris Inc., MBX Biosciences Inc., Crinetics Pharmaceuticals Inc., Vidasym Inc., Rani Therapeutics LLC, Pathalys Pharma Inc.

Access The Complete Parathyroid Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/parathyroid-disease-treatment-global-market-report

Which Regional Market Leads The Parathyroid Disease Treatment Market?

Asia-Pacific was the largest region in the parathyroid disease treatment market in 2025. The regions covered in the parathyroid disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Parathyroid Disease Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=25866&type=smp

Browse Through More Reports Similar to the Global Parathyroid Disease Treatment Market 2026, By The Business Research Company

Transthyretin Amyloidosis Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/transthyretin-amyloidosis-treatment-global-market-report

Anti Thyroid Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-thyroid-drugs-global-market-report

Thyroid Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795